[EGLT] Egalet Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 8.45 Change: 0.33 (4.06%)
Ext. hours: Change: 0 (0%)

chart EGLT

Refresh chart

Strongest Trends Summary For EGLT

EGLT is in the long-term down -100% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Egalet Corporation, a specialty pharmaceutical company, is engaged in developing planning to commercialize proprietary, abuse-deterrent pharmaceutical products for the treatment of pain and other indications. It develops various clinical-stage opioid-based product candidates through its technology platform in tablet form that are specifically designed to deter abuse by physical and chemical manipulation while also providing tailored release of the active pharmaceutical ingredient. The company?s product candidates include Egalet-001 and Egalet-002 that are abuse-deterrent, extended-release, oral formulations for the treatment of moderate and severe pain. It is also developing a portfolio of preclinical abuse-deterrent product candidates for the treatment of pain and other conditions. The company was founded in 2010 and is headquartered Wayne, Pennsylvania.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 64.29% Sales Growth - Q/Q-2.54% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-54.15% ROE-166.92% ROI
Current Ratio2.52 Quick Ratio Long Term Debt/Equity Debt Ratio0.97
Gross Margin Operating Margin-1931.55% Net Profit Margin-1904.37% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities14.61 M Cash From Investing Activities-13.46 M Cash From Operating Activities160 K Gross Profit330 K
Net Profit-16.72 M Operating Profit-16.35 M Total Assets86.84 M Total Current Assets68.96 M
Total Current Liabilities27.38 M Total Debt17.01 M Total Liabilities58.67 M Total Revenue810 K
Technical Data
High 52 week1.14 Low 52 week Last close0.01 Last change0%
RSI59.4 Average true range Beta1.58 Volume554.56 K
Simple moving average 20 days26.74% Simple moving average 50 days-50.15% Simple moving average 200 days-98.31%
Performance Data
Performance Week25% Performance Month-24.24% Performance Quart-95.45% Performance Half-98.73%
Performance Year-99.51% Performance Year-to-date100% Volatility daily30.46% Volatility weekly68.12%
Volatility monthly139.6% Volatility yearly483.57% Relative Volume359.83% Average Volume467.43 K
New High New Low

News

2019-09-06 10:33:28 | Edited Transcript of EGLT earnings conference call or presentation 13-Aug-19 8:30pm GMT

2019-05-17 08:16:58 | Edited Transcript of EGLT earnings conference call or presentation 16-May-19 8:30pm GMT

2018-12-03 15:01:37 | [$$] Egalet Gets Approval to Put Reorganization Plan to Creditor Vote

2018-11-27 12:10:48 | [$$] Firm Retention Summary: Egalet Corp.

2018-11-19 06:15:25 | Egalet: 3Q Earnings Snapshot

2018-11-19 06:02:00 | Egalet Reports Third Quarter 2018 Financial Results

2018-11-07 10:30:03 | Will Egalet EGLTQ Report Negative Earnings Next Week? What You Should Know

2018-11-01 14:00:00 | EGLT: Egalet Recapitalization

2018-11-01 10:58:02 | [$$] Nine West Directors Caught in Bankruptcy Crossfire

2018-10-31 14:49:35 | [$$] Drugmaker Egalet Files for Chapter 11 Bankruptcy

2018-10-31 06:04:00 | Egalet Signs Asset Purchase Agreement to Acquire Four FDA-Approved, Non-Narcotic Pain Products

2018-09-26 08:36:38 | [$$] Drug Maker Egalet Buys More Times With Bondholder Pact

2018-09-25 18:10:40 | [$$] Egalet Enters Forbearance Pact With Some Bondholders

2018-08-31 08:25:00 | New Research Coverage Highlights Argos Therapeutics, Triumph Group, Rigel Pharmaceuticals, Egalet, Hertz Global, and ACADIA Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-08-27 12:15:00 | EGLT: Egalet 2Q:18 Results

2018-08-14 05:30:19 | Edited Transcript of EGLT earnings conference call or presentation 8-Aug-18 12:30pm GMT

2018-08-08 06:30:00 | Egalet Corporation to Host Earnings Call

2018-08-08 06:10:24 | Egalet: 2Q Earnings Snapshot

2018-08-08 06:02:00 | Egalet Reports Second Quarter 2018 Financial Results

2018-08-07 14:35:32 | Preview: Egalet's Q2 Earnings

2018-07-27 07:40:00 | Market Trends Toward New Normal in Egalet, PPG Industries, Synergy Pharmaceuticals, Equity Residential, Array BioPharma, and Holly Energy Partners — Emerging Consolidated Expectations, Analyst Ratings

2018-07-25 06:02:00 | Egalet to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results on August 8, 2018

2018-06-18 07:20:00 | Free Daily Technical Summary Reports on Dermira and Three Other Biotech Stocks

2018-06-07 06:02:00 | Egalet Appoints Industry Veteran John Varian to Board of Directors

2018-06-04 06:02:00 | Egalet to Participate in Panels at 2018 BIO International Convention and JMP Life Sciences Conference

2018-05-29 06:02:00 | Egalet Announces Large Regional Plan to Cover SPRIX® Nasal Spray

2018-05-22 07:30:00 | Report: Developing Opportunities within Integer, Sykes Enterprises, Protagonist Therapeutics, Egalet, Watsco, and Extra Space Storage — Future Expectations, Projections Moving into 2018

2018-05-16 19:07:09 | Breakeven On The Horizon For Egalet Corporation NASDAQ:EGLT

2018-05-14 11:00:00 | EGLT: Partnerships and Formulary Adds Impressive; Waiting for Revenue Catch Up

2018-05-08 19:46:01 | Edited Transcript of EGLT earnings conference call or presentation 8-May-18 12:30pm GMT

2018-05-08 06:07:13 | Egalet: 1Q Earnings Snapshot

2018-05-08 06:02:00 | Egalet Reports First Quarter 2018 Financial Results

2018-05-07 06:02:00 | Egalet Announces National Pharmacy Benefit Manager to Cover SPRIX® Nasal Spray and ARYMO® ER

2018-05-02 06:02:00 | Egalet to Present at the 3rd Annual Disruptive Growth & Healthcare Conference

2018-04-30 06:02:00 | Egalet Presented Data at American Academy of Pain Medicine Examining the Potential of ARYMO® ER to Deter Opioid Abuse

2018-04-24 06:02:00 | Egalet to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results on May 8, 2018

2018-04-20 07:00:00 | Free Post Earnings Research Report: Egalet's Q4 Top-Line Growth Beat Estimates

2018-04-17 16:02:00 | Egalet Announces Two Large Northeast Regional Health Plans Placed ARYMO® ER in Preferred Formulary Position

2018-04-02 10:30:00 | EGLT: Costs Down, Revenues Up, Partnerships Expanding

2018-03-28 07:40:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Clifton, CSG Systems International, ArcelorMittal, Denny's, Yamana Gold, and Egalet — New Research Emphasizes Economic Growth

2018-03-23 12:03:34 | Egalet CEO: 'We are moving the company closer and closer to profitability'

2018-03-22 15:50:33 | Auditor raises questions about Egalet's future

2018-03-22 14:26:46 | [$$] Drug Maker Egalet Raises 'Going Concern' warning

2018-03-21 06:02:00 | Egalet to Present at Upcoming Conferences

2018-03-13 02:55:29 | Edited Transcript of EGLT earnings conference call or presentation 12-Mar-18 12:30pm GMT

2018-03-12 07:00:00 | Egalet Corporation to Host Earnings Call

2018-03-12 06:29:47 | Egalet posts 4Q profit

2018-03-12 06:02:00 | Egalet Reports Fourth Quarter and Full Year 2017 Financial Results

2018-02-28 06:02:00 | Egalet Announces a Large Regional Health Plan Placed ARYMO® ER and SPRIX® Nasal Spray in Preferred Formulary Positions

2018-02-26 16:02:00 | Egalet to Host Conference Call and Webcast to Discuss Fourth Quarter and Year-End 2017 Financial Results on March 12, 2018